SML3105
K-7174 dihydrochloride
≥98% (HPLC)
Synonym(s):
1,4-bis((E)-5-(3,4,5-Trimethoxyphenyl)pent-4-enyl)-1,4-diazepane dihydrochloride, K 7174 dihydrochloride, K7174 dihydrochloride, N,N?-bis-(E)-[5-(3,4,5-Trimethoxyphenyl)-4-pentenyl]homopiperazine dihydrochloride
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C33H48N2O6 · 2HCl
CAS Number:
Molecular Weight:
641.67
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
InChI key
JKAQFPBRMVEHBD-CHBZAFCASA-N
SMILES string
COC(C(OC)=C1)=C(C=C1/C=C/CCCN(CCC2)CCN2CCC/C=C/C3=CC(OC)=C(C(OC)=C3)OC)OC.[H]Cl.[H]Cl
assay
≥98% (HPLC)
form
powder
Quality Level
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
−20°C
Related Categories
Biochem/physiol Actions
K-7174 is a homopiperazine with dual GATA and proteasome inhibitory activtiy. K-7174 selective inhibts GATA-mediated gene regulations in cultures (10-30 μM; VCAM-1 expression in HUVECs or Epo suppression in Hep3B cells) and in vivo (30 mg/kg in mice via i.p. against IL-1beta- or TNF-alpha-induced anemia). K-7174 exhibits anti-myeloma activity in vitro (10-25 μM) and in vivo (50 mg/kg/day p.o. in mice) by targeting the active pockets of β1, β2 and β5 subunits of proteasome along hydrophobic grooves in the direction of the β7, β1 and β4 subunits in a manner distinct from that of bortezomib.
Orally active, dual GATA and proteasome inhibitor in vitro and in vivo.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yosuke Takano et al.
Biochemical and biophysical research communications, 360(2), 470-475 (2007-07-03)
K-7174, a GATA-specific inhibitor, is a putative anti-inflammatory agent that attenuates effects of inflammatory cytokines in certain cell types. However, molecular mechanisms involved have not been elucidated. We found that, in glomerular podocytes, induction of monocyte chemoattractant protein 1 (MCP-1)
Shigehiko Imagawa et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 17(12), 1742-1744 (2003-09-06)
Interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), or N(G)-monomethyl-L-arginine (L-NMMA) are increased in patients with chronic disease-related anemia. They increase the binding activity of GATA and inhibit erythropoietin (Epo) promoter activity. In this study, we examined the ability of K-7174 (a
Sergio Martinez-Høyer et al.
Nature cell biology, 22(5), 526-533 (2020-04-07)
Interstitial deletion of the long arm of chromosome 5 (del(5q)) is the most common structural genomic variant in myelodysplastic syndromes (MDS)1. Lenalidomide (LEN) is the treatment of choice for patients with del(5q) MDS, but half of the responding patients become
M Umetani et al.
Biochemical and biophysical research communications, 272(2), 370-374 (2000-06-02)
A novel inhibitor for the adhesion of monocytes to cytokine-stimulated endothelial cells, K-7174, was selected by an assay system using the cultured human monocytic cells and human endothelial cells. K-7174 inhibited the expression of vascular cell adhesion molecule-1 (VCAM-1) induced
Jiro Kikuchi et al.
The Journal of biological chemistry, 288(35), 25593-25602 (2013-07-24)
Bortezomib therapy is now indispensable for multiple myeloma, but is associated with patient inconvenience due to intravenous injection and emerging drug resistance. The development of orally active proteasome inhibitors with distinct mechanisms of action is therefore eagerly awaited. Previously, we
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service